Syngeneic Mouse Models and Humanized Immune-Checkpoint Mice

June 17, 2020

Why do we need Syngeneic Mouse Models? To test potential immuno-oncology therapeutics in vivo, it is necessary to ensure that the disease model used has an intact immune system. Immunotherapeutics work with the body’s immune system to fight cancer cells. Often through inhibiting specific cell receptors called immune checkpoints, immunotherapeutics seek to bind to receptors […]

Read More

Gene Targeting Service Verified with Industry-leading Quality Control Measures

March 12, 2020

  At Biocytogen, we take pride in our quality control measures when we target and edit genes for our mouse models and drug development endeavors. From preventing potentially disastrous results before they occur to instituting reliable, tried-and-true protocols, proper attention to quality control when gene-editing can save clients both time and resources. For example, based […]

Read More

Knock In and Knock Out Mice as Powerful Disease Models

March 3, 2020

Why Do We Care About Gene-edited Mice? The generation of knockout and knock-in animal models has allowed not only disease research but also the development of disease-fighting drugs. The Nobel Prize for Physiology and Medicine recognized Evans, Smithies, and Capecchi for their joint effort in creating the first knockout mouse over two decades ago in […]

Read More

The Utility of the Rosa26 Knock-in Mouse

November 19, 2019

The Rosa26 locus in the mouse genome is a “safe harbor” which allows researchers to express genes of interest. Different gene targeting technologies (embryonic stem cells; CRISPR) are used to make specific DNA insertions at the Rosa26 locus. The rationale for scientists to use Rosa26 and other key benefits to using this type of mouse […]

Read More

Back to top